Share

    


In This Section

Home / Archived Webinar Details

Webinar: Emerging Role of Immunotherapy in Metastatic Merkel Cell Carcinoma

View the archived ICLIO Webinar: Emerging Role of Immunotherapy in Metastatic Merkel Cell Carcinoma with expert presenter, Brent Hanks, MD, PhD, Assistant Professor of Medicine, Duke Cancer Institute.

Watch WebinarDownload Slides

The March 2017 FDA approval of avelumab, a PD-L1 checkpoint inhibitor, for patients with metastatic Merkel cell carcinoma (MCC) provides a new treatment option for this rare skin cancer. Review the current treatment algorithm and clinical evidence supporting immunotherapies in MCC patients. Learn about other immuno-oncology agents in development, and the potential challenges and concerns related to metastatic MCC.